42 search results for: disease progression

The Impact of Advanced Systemic Therapies on <b>Disease</b> Control and Potential Remission in Atopic Dermatitis

expert video

The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis

10 min

Dermatology

Exploring the concept of disease modification relating to therapeutic interventions with targeted systemic therapies in atopic dermatitis.

expert video

UEGW 2023 | Burden of EoE and Multidimensional Assessment of Disease

10 min

Gastroenterology

Dr. Christoper Ma explores the burden of disease in EoE and the multiple dimensions of disease to assess in patients with EoE.

UEGW 2023 | Expanding Horizons in EoE: The Journey to Long-term <b>Disease</b> Control

expert video

UEGW 2023 | Expanding Horizons in EoE: The Journey to Long-term Disease Control

46 min

Gastroenterology

Join Prof. Christoph Schlag and Dr. Christoper Ma for an educational presentation about the journey to long-term disease control in EoE.

expert video

Type 2 Inflammation in EoE and Impact on Disease Burden

20 min

Gastroenterology

Dr. Seema Aceves discusses the role of type 2 inflammation in EoE pathophysiology and disease burden.

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

5 min

Dermatology

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

5 min

Dermatology

An infographic exploring the process of allergen sensitization and the impact it may have on the development of atopic comorbidities in children with AD.

expert video

Evolving Topics in Type 2 Inflammation

49 min

Type 2 Inflammation

Drs. Eric Simpson, Jonathan Spergel, and Profs. Francesca Puggioni, Ian Pavord, Peter Hellings discuss emerging topics in type 2 inflammatory diseases

expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

15 min

Dermatology

Exploring the concept of disease modification through early intervention with targeted systemic therapies in atopic dermatitis.

videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

3 min

Gastroenterology

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwedenChange country/region